Capitainer Secures SEK 30 Million Investment from We Venture Capital to Expand and Innovate in Self-Sampling Solutions
Capitainer is proud to announce a significant financial investment of SEK 30 million from We Venture Capital, the venture capital arm of the globally renowned Werfen Group. This strategic investment marks a milestone in Capitainer's journey towards becoming the foremost provider of self-sampling solutions.
We Venture Capital, the venture capital arm of Werfen Group which reported a turnover of 1.84 billion dollars in 2022, specializes in empowering innovative companies at the forefront of diagnostic technology. This investment aligns with their mission of transforming patient-oriented diagnostic solutions.
This funding will fuel Capitainer’s expansion efforts, including scaling up production capacity, enhancing sales and marketing strategies, and launching new products. The investment will be administered in two phases: an initial SEK 15 million followed by an additional SEK 15 million, contingent upon Capitainer achieving specific milestones.
Alongside the substantial investment from We Venture Capital, Sciety—a leading investment company supporting life science companies in the Nordics and an investor in Capitainer since 2021—has further solidified its investment in Capitainer by participating in this funding round. This collaborative investment effort underscores the confidence in Capitainer’s vision and potential.
"Receiving an investment from an industry-leading venture capital company like We Venture Capital is a significant seal of approval," says Christopher Aulin, CEO at Capitainer. "This investment is a testament to our innovative approach in self-sampling solutions and also a strategic alliance that will propel our efforts in enhancing product validation, expanding our market reach, and establishing a stronghold in the industry."
"We are very impressed by the product performance and what the Capitainer team has achieved the last few years. The product portfolio is disruptive and innovative and demonstrates very solid data. We look forward to supporting Capitainer on their future journey," says Louise Warme, head of We Venture Capital.
The investment from We Venture Capital marks the beginning of an investment relationship. Capitainer looks forward to the support and collaboration with the We Venture Capital team.
For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Email: christopher.aulin@capitainer.com
About Capitainer
Capitainer AB is a Swedish MedTech company that develops and sells patient-centric solutions for self-sampling of blood, plasma, and urine. Founded in 2016, Capitainer has developed unique technologies for collecting and drying exact volumes of fluid within easy-to-use sampling cards. These cards may be sent as standard post to relevant testing laboratories, thus bypassing the need for cold chain logistics and specialised packaging. Capitainer’s products are market-leading with respect to precision and accuracy, with demonstrated equal performance to established pipetting methods. The products are applicable within several market segments, including but not limited to, clinical biomarkers, therapeutic drug monitoring, genomics, drug abuse and doping testing, and R&D and clinical studies.
About We Venture Capital
We Venture Capital is a specialized fund investing in diagnostics, as well as tools and digital solutions in the diagnostics area. Being the corporate investment arm of Werfen, a worldwide leader in specialized diagnostics, We Venture Capital is an active investor, leveraging the network and knowledge from Werfen to the benefit of our investments.
We invest in and partner with early-stage startups close to market entry or early scale-ups, working close with our portfolio to support their growth over time. We are firm believers of technical advancement as a means to improve patient outcomes and revolutionize healthcare.
About Sciety
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world. For more information, please visit www.sciety.com and follow us on LinkedIn.
Tags:
